-+ 0.00%
-+ 0.00%
-+ 0.00%

Embla Medical narrows 2026 organic sales growth outlook to 5%-7%

PUBT·07/21/2026 08:55:18
Listen to the news
Embla Medical narrows 2026 organic sales growth outlook to 5%-7%
  • Embla Medical narrowed 2026 guidance to 5-7% organic sales growth, down from 5-8%; EBITDA margin before special items kept at 20-22%.
  • Update followed Q2 reported sales growth of 11%, including 3 percentage points from M&A and 2 percentage points from FX; organic growth was 6%.
  • Q2 EBITDA margin was 22%; gross margin was 63%, including a USD 3 million net tariff refund that lifted gross margin by about 1 percentage point.
  • Patient Care weighed on performance, with sales below expectations in EMEA due to soft conditions in key European markets; Americas and APAC showed progress.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Embla Medical hf. published the original content used to generate this news brief on July 21, 2026, and is solely responsible for the information contained therein.